• Day One Biopharmaceuticals Inc DAWN.OQ reported a quarterly adjusted loss of 19 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -37 cents. The mean expectation of nine analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -32 cents to -26 cents per share.

• Revenue rose 91.9% to $38.52 million from a year ago; analysts expected $38.20 million.

• Day One Biopharmaceuticals Inc's reported EPS for the quarter was a loss of 19 cents​.

• The company reported a quarterly loss of $19.73 million.

• Day One Biopharmaceuticals Inc shares had risen by 3.7% this quarter and lost 42.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.5% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc is $25.00, about 70.8% above its last closing price of $7.31

This summary was machine generated from LSEG data November 4 at 10:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)